IND 22 - Latest Innovations and a Glimpse into the Future of Contrast-Enhanced MRI

Gadolinium-based contrast agents (GBCAs) have been used in over 800 million contrast-enhanced MRI (CE-MRI) applications worldwide in both patient diagnosis and follow-up scans. The unique in-vivo properties of GBCAs have enabled their widespread adoption, providing valuable diagnostic information across a broad range of indications and serving as an effective option for enhancing the MRI signal intensity.

We provide an important update for all those involved in CE-MRI. This session will focus on the latest innovations and ongoing developments in macrocyclic GBCAs. An expert multi-specialty panel will discuss the potential of optimized utilization of contrast agents in the context of international guidelines and patient preferences, setting the scene for the future of CE-MRI.

Gadoquatrane has not been approved in the European Union.


Learning Objectives:
• Understand the important role of GBCAs in MRI during diagnosis and patient follow up
• Explore latest innovations in GBCAs including an update of ongoing clinical development
• Discuss future directions in CE-MRI with the background of international imaging guidelines, environmental sustainability and patient preferences
PP-GD-ALL-0002-1 11.2024